- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07836478
Neurocognitive Integrity After Proton Therapy for Brain Tumor (PROTON MIND)
Prospective Evaluation of Neurocognitive Integrity After Proton Therapy for Brain Tumor
Radiation therapy remains a cornerstone in the management of both benign and malignant intracranial tumors, either as monotherapy or combined with surgery and/or chemotherapy. Despite its therapeutic benefits, it is frequently associated with potential long-term adverse effects, with neurotoxicity posing a major challenge, especially in young patients affected by benign primary tumors.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
In the brain, late radiotoxicities typically manifest as cognitive dysfunction, leukoencephalopathy, brain atrophy, brain tissue necrosis, cerebrovascular complications, endocrinopathies, and/or secondary malignant neoplasms.
Radiation-induced hippocampal injury, in particular, significantly contributes to cognitive impairment, while broader central nervous system effects arise through multiple mechanisms, including vascular injury, neuronal depletion, chronic inflammation, demyelination, and tissue necrosis.
The severity of cognitive dysfunction depends on multiple factors, including the location and the volume of the tumor, the total radiation dose administered, the fractionation regimen, and the individual susceptibility of the patient, as well as comorbidities (e.g., diabetes, etc.) and concomitant drugs.
The distinct physical characteristics of proton therapy, such as a reduced entrance dose, an eliminated exit dose, and a Bragg peak, provide clear dosimetric advantages over conventional photon treatments. Pencil-beam scanning further improves on earlier passive scattering approaches by delivering modulated proton beamlets for superior target conformality and reduced neutron scatter, thereby limiting low- and intermediate- dose exposure to cranial organs at risk (OARs) while preserving adequate dose coverage within the target volume.
From a radiobiological standpoint, these properties suggest that proton therapy may present a more favorable risk-benefit balance compared to photon-based modalities, particularly for long-term clinical outcomes. It achieves a drastic reduction in the integral dose, offering substantial benefit in decreasing radiation-induced second malignancies, making it mandatory for children when available.
Proton therapy is well established for treating pediatric tumors, CNS tumors such as low-grade gliomas (LGG) and meningiomas, especially if near the optic pathway or brainstem, and all the benign tumors in young patients. In these cases, the primary goal extends beyond curing the disease to preserving neurological and cognitive functions.
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Gabriella Pravettoni
- Numero di telefono: +39 0257489207
- Email: Gabriella.Pravettoni@ieo.it
Luoghi di studio
-
-
Italy
-
Milan, Italy, Italia, 20141
- European Institute of Oncology, Milan
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Patients affected by primary central nervous system tumors and eligible for protontherapy as adjuvant or radical treatment
Descrizione
Inclusion Criteria:
- Primary tumors of Brain Tumor (CNS), benign and malignant
- Age ≥ 18 years
- Patients able to speak and read the local language(s) fluently
- Acceptance and signature of informed consent
- Radiological diagnosis, biopsy, or previous surgery
- Concomitant medical therapy is allowed
Exclusion Criteria:
- Previous brain radiotherapy (any form)
- High-grade gliomas
- Patients with concomitant neurological or psychiatric disorders.
- Pregnancy
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The presence of cognitive impairment
Lasso di tempo: From the end of Protontherapy through study completion, an average of 1 year.
|
The primary endpoint will be the presence of cognitive impairment during the first 5 years after enrollment, as measured by a comprehensive neuropsychological assessment. |
From the end of Protontherapy through study completion, an average of 1 year.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Perceived cognitive impairment
Lasso di tempo: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Functional Assessment of Cancer Therapy-cognition (FACT-cog) 37 items will be completed (score 1-4) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Depressive symptoms
Lasso di tempo: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
At Beck Depression Inventory-II (BDI-II) 21 items will be completed (score 0-3) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Anxiety
Lasso di tempo: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For State-Trait Anxiety Inventory (STAI) 40 items will be completed (score 1-4) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Quality of Life data (QoL) - EORTC QLQ C30 questionnaires.
Lasso di tempo: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For EORTC QLQ C30, 30 items will be completed (score 1-4). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Sleep quality
Lasso di tempo: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Pittsburgh Sleep Quality Index (PSQI) 24 items will be completed (score 0-3) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Cognitive Reserve
Lasso di tempo: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Cognitive Reserve Index questionnaire (CRIq) 20 items will be completed (core 0-1) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Global functioning
Lasso di tempo: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Montreal Cognitive Assessment (MoCA) 30 items will be completed (score 1-5). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Learning and Verbal Memory
Lasso di tempo: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Rey Auditory Verbal Learning Test (RAVLT) 15 items will be completed (score 0-4). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Working memory
Lasso di tempo: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Corsi Span backward/forward 18 items will be completed (score 0-4). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Visual memory
Lasso di tempo: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Rey-Osterrieth complex figure -recall 18 items will be completed (score 0-2). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Visuospatial abilities
Lasso di tempo: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Rey-Osterrieth complex figure -copy 18 items will be completed (score 0-2). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Executive function
Lasso di tempo: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Frontal Assessment Battery (FAB) 30 items will be completed (score 0-3). |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
|
Attention
Lasso di tempo: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
For Symbol digit modalities test (SDMT) 110 items will be completed (score 0-1) |
At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- UID 5445
- L2-684 (Altro identificatore: Comitato Etico Lombardia 2)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .